IOL Chemicals & Pharmaceuticals Share News - Latest Updates, Live News & More

Latest news about IOL Chemicals & Pharmaceuticals

IOL Chemicals Reports 33% EBITDA Growth in Q2 FY26 Despite Flood-Related Cost Pressures Nov 19, 2025

IOL Chemicals & Pharmaceuticals Limited (IOLCP) reported robust Q2 FY26 results with revenue up 7.9% to INR 567.50 crores, EBITDA up 33.3% to INR 64.00 crores, and PAT up 56.7% to INR 30.00 crores. Growth was driven by non-Ibuprofen API volume recovery, stable product mix, and cost efficiency. The pharmaceuticals segment contributed 59% to revenue, with Ibuprofen accounting for 62% of that. The new paracetamol facility reached 55% capacity utilization. Despite temporary margin pressure from Punjab floods, IOLCP aims for 13-14% EBITDA margins and 10-15% annual revenue growth, focusing on regulated markets expansion.

IOL Chemicals & Pharmaceuticals Unveils Growth Strategy: Capacity Expansion and API Diversification Nov 12, 2025

IOL Chemicals Reports 11.7% Decline in Q2 Net Profit, Revenue Grows 2.9% Nov 11, 2025

IOL Chemicals Secures EDQM Certificate for Antidiabetic API Oct 27, 2025

IOL Chemicals and Pharmaceuticals Expands Global Footprint with UK Subsidiary Oct 24, 2025

More news about IOL Chemicals & Pharmaceuticals

15Oct 25

IOL Chemicals Secures European Certificate for Pantoprazole API, Expanding Market Reach

IOL Chemicals & Pharmaceuticals (IOLCP) has obtained a Certificate of Suitability from the European Directorate for the Quality of Medicines & Health Care (EDQM) for its Pantoprazole Sodium Sesquihydrate Process-III API product. This certification validates the quality and compliance of IOLCP's manufacturing process for this proton pump inhibitor, used in treating various gastrointestinal conditions. The achievement could potentially expand IOLCP's presence in the European pharmaceutical market, known for its strict quality standards, and may lead to increased export revenues and enhanced global reputation.

13Aug 25

IOL Chemicals Reports 9.8% Revenue Growth and 19.5% EBITDA Jump in Q1

IOL Chemicals & Pharmaceuticals reported robust Q1 FY24 results with revenue up 9.8% to Rs. 552.00 crores, EBITDA rising 19.5% to Rs. 69.50 crores, and PAT growing 14.4% to Rs. 34.00 crores. The company's new Paracetamol plant has begun exports to Europe, operating at 34% capacity. Export revenue comprises 25% of total sales, with plans to increase to 40%. The company received REACH registration for Acetic Anhydride in EU markets and is setting up Unit 9B for Minoxidil production. IOL Chemicals maintains its guidance of 14-15% EBITDA margins and 10% revenue growth for the full year, aiming for Rs. 2,000.00 crores in revenue from Ibuprofen and non-Ibuprofen segments within two years.

07Aug 25

IOL Chemicals Unveils Strategic Expansion Plan Amid Strong Q1 Performance

IOL Chemicals & Pharmaceuticals has revealed a strategic expansion plan focusing on high-value APIs, global market penetration, and backward integration. The company is targeting non-Ibuprofen API expansion, has obtained REACH registration for Acetic Anhydride in the EU, and is setting up a new unit for Minoxidil production. A wholly-owned UK subsidiary is also planned. Q1 financial results show revenue at ₹551.69 crore (up 9.8% YoY), EBITDA at ₹69.50 crore (up 19.5% YoY), and PAT at ₹34.00 crore (up 14.4% YoY). The Pharmaceuticals segment remains the primary revenue and profit driver.

07Aug 25

IOL Chemicals and Pharmaceuticals Reports Strong Q1 Performance, Plans UK Subsidiary and Minoxidil Production

IOL Chemicals & Pharmaceuticals announced strong Q1 results with a 9.8% revenue increase to ₹551.69 crore and a 14.5% rise in net profit to ₹34.00 crore. The company's EBITDA grew to ₹62.10 crore with an improved margin of 11.3%. The pharmaceutical segment led revenue generation at ₹329.33 crore. The Board approved establishing a wholly-owned subsidiary in the UK and plans to manufacture Minoxidil with a 120 MTPA capacity at a new Unit 9B, investing ₹5.50 crore from internal funds. The project is set for completion by December 2025.

13Jun 25

IOL Chemicals Secures EU REACH Registration for Acetic Anhydride

IOL Chemicals & Pharmaceuticals has successfully registered Acetic Anhydride under the European Union's REACH regulation. This achievement allows the company to export the product to all EU member states, potentially enhancing its global presence and opening new revenue streams in the European market. The registration demonstrates IOL's compliance with international regulatory standards and its commitment to expanding its global footprint.

16May 25

IOL Chemicals: Q4 Net Profit Rises 13.7%, Margins Expand

IOL Chemicals and Pharmaceuticals Ltd announced impressive Q4 financial results. EBITDA increased by 28.5% to ₹62.60 crore, with EBITDA margin improving to 11.80%. Net profit rose by 13.7% to ₹31.42 crore, while revenue grew by 4.7% to ₹527.70 crore. The company demonstrated improved operational efficiency and effective cost management.

24Mar 25

IOL Chemicals and Pharma Boosts Production Capacity with New Paracetamol Unit and Clopidogrel Expansion

IOL Chemicals and Pharmaceuticals Limited (IOLCP) has significantly expanded its production capabilities. The company launched a new Paracetamol production unit with a capacity of 10,800 MTPA, increasing total capacity to 14,400 MTPA. IOLCP also expanded its Clopidogrel Bisulphate manufacturing capacity from 180 MTPA to 240 MTPA. The Paracetamol expansion cost Rs 155.51 crore, while the Clopidogrel expansion required Rs 7.87 crore, both funded through internal accruals. The new Paracetamol unit includes backward integration with in-house production of key intermediates.